GVHD-free survival, frequency of macroengraftment, and PB chimerism after co-injection of various subpopulations with TCD BM into newborn pups at 20 DPC
| Cells co-injected with TCD BM . | Number of cells injected (millions) . | Number of mice injected . | GVHD-free survival, n (%) . | Frequency of macroengraftment among survivors, n (%) . | Mean chimerism at 4 weeks among survivors, % . |
|---|---|---|---|---|---|
| None | 0 | 90 | 90 (100) | 4 (4) | 0.2 |
| Naive mice | |||||
| B6 (H2kb) CD4+ | 5.0 | 11 | 4 (36) | 0 (0) | 0 |
| Balb/c (H2kd) CD4+ | 5.0 | 8 | 8 (100) | 0 (0) | 0 |
| Chimeric mice | |||||
| All (H2kd+ and H2kb+) CD4+ | 5.0 | 24 | 24 (100) | 24 (100) | 7.3 |
| Host-derived (H2kd+) | 2.5 | 10 | 10 (100) | 10 (100) | 5.6 |
| CD25− | 2.25 | 15 | 15 (100) | 6 (40) | 2.0 |
| CD25+ | 0.25 | 7 | 7 (100) | 6 (86) | 5.5 |
| Donor-derived (H2kb+) | 1.0 | 9 | 9 (100) | 6 (67) | 5.4 |
| CD25− | 0.95 | 8 | 8 (100) | 6 (75) | 2.6 |
| IL-10+ | 0.04 | 7 | 7 (100) | 1 (14) | 0.3 |
| Cells co-injected with TCD BM . | Number of cells injected (millions) . | Number of mice injected . | GVHD-free survival, n (%) . | Frequency of macroengraftment among survivors, n (%) . | Mean chimerism at 4 weeks among survivors, % . |
|---|---|---|---|---|---|
| None | 0 | 90 | 90 (100) | 4 (4) | 0.2 |
| Naive mice | |||||
| B6 (H2kb) CD4+ | 5.0 | 11 | 4 (36) | 0 (0) | 0 |
| Balb/c (H2kd) CD4+ | 5.0 | 8 | 8 (100) | 0 (0) | 0 |
| Chimeric mice | |||||
| All (H2kd+ and H2kb+) CD4+ | 5.0 | 24 | 24 (100) | 24 (100) | 7.3 |
| Host-derived (H2kd+) | 2.5 | 10 | 10 (100) | 10 (100) | 5.6 |
| CD25− | 2.25 | 15 | 15 (100) | 6 (40) | 2.0 |
| CD25+ | 0.25 | 7 | 7 (100) | 6 (86) | 5.5 |
| Donor-derived (H2kb+) | 1.0 | 9 | 9 (100) | 6 (67) | 5.4 |
| CD25− | 0.95 | 8 | 8 (100) | 6 (75) | 2.6 |
| IL-10+ | 0.04 | 7 | 7 (100) | 1 (14) | 0.3 |